RT Journal Article
SR Electronic
T1 Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study
JF Journal of Neurology, Neurosurgery & Psychiatry
JO J Neurol Neurosurg Psychiatry
FD BMJ Publishing Group Ltd
SP 849
OP 857
DO 10.1136/jnnp-2021-328568
VO 93
IS 8
A1 Ingrid Anne Lie
A1 Sezgi Kaçar
A1 Kristin Wesnes
A1 Iman Brouwer
A1 Silje S Kvistad
A1 Stig Wergeland
A1 Trygve Holmøy
A1 Rune Midgard
A1 Alla Bru
A1 Astrid Edland
A1 Randi Eikeland
A1 Sonia Gosal
A1 Hanne F Harbo
A1 Grethe Kleveland
A1 Yvonne S Sørenes
A1 Nina Øksendal
A1 Kristin N Varhaug
A1 Christian A Vedeler
A1 Frederik Barkhof
A1 Charlotte E Teunissen
A1 Lars Bø
A1 Øivind Torkildsen
A1 Kjell-Morten Myhr
A1 Hugo Vrenken
YR 2022
UL http://jnnp.bmj.com/content/93/8/849.abstract
AB Background The predictive value of serum neurofilament light chain (sNfL) on long-term prognosis in multiple sclerosis (MS) is still unclear.Objective Investigate the relation between sNfL levels over a 2-year period in patients with relapsing-remitting MS, and clinical disability and grey matter (GM) atrophy after 10 years.Methods 85 patients, originally enrolled in a multicentre, randomised trial of ω−3 fatty acids, participated in a 10-year follow-up visit. sNfL levels were measured by Simoa quarterly until month 12, and then at month 24. The appearance of new gadolinium-enhancing (Gd+) lesions was assessed monthly between baseline and month 9, and then at months 12 and 24. At the 10-year follow-up visit, brain atrophy measures were obtained using FreeSurfer.Results Higher mean sNfL levels during early periods of active inflammation (Gd+ lesions present or recently present) predicted lower total (β=−0.399, p=0.040) and deep (β=−0.556, p=0.010) GM volume, lower mean cortical thickness (β=−0.581, p=0.010) and higher T2 lesion count (β=0.498, p=0.018). Of the clinical outcomes, higher inflammatory sNfL levels were associated with higher disability measured by the dominant hand Nine-Hole Peg Test (β=0.593, p=0.004). Mean sNfL levels during periods of remission (no Gd+ lesions present or recently present) did not predict GM atrophy or disability progression.Conclusion Higher sNfL levels during periods of active inflammation predicted more GM atrophy and specific aspects of clinical disability 10 years later. The findings suggest that subsequent long-term GM atrophy is mainly due to neuroaxonal degradation within new lesions.Data are available upon reasonable request.